Detoxification From the Lipid Tract

Summary

Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.

Conditions

• COVID-19 Vaccine Adverse Reaction

Interventions

DEVICE

electroencephalogram biofeedback

EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.

DEVICE

electrical brain stimulation

EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.

DEVICE

ultra-low frequency transcranial magnetic stimulation

ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.

DRUG

Sertraline Hydrochloride

Sertraline is taken in the morning for 150 mg per day.

DRUG

Clonazepam

Clonazepam is taken in the morning for 1 mg per day.

DRUG

Alprazolam

Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.

DRUG

Metoprolol

Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.

DRUG

Olanzapine

Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.

DRUG

Pravastatin Sodium 20 MG

Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.

DRUG

Sacubitril Valsartan Sodium Hydrate

Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.

Sponsors & Collaborators

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Pachankis, Yang I., M.D.

  lead INDIV

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-02-26

Primary Completion

2024-03-14

Completion

2024-03-20

Countries

• China

Study Locations